T-Bolt antibody platform targeting peptide-HLA complexes from intracellular proteins; CBX-250 in CROSSCHECK-001 Phase 1 across AML/CML/MDS/CMML; CBX-663 IND in Q3 2026; cumulative $157M
No detailed funding rounds available.
Total known funding: